natgillin/translations-raw huggingface dataset:
Tell your doctor if you get these symptoms.
Če se vam pojavita ta simptoma, morate to povedati svojemu zdravniku.
This medicinal product is authorised in the Member States of the EEA under the following names:
To zdravilo je odobreno v državah članicah EGP pod naslednjimi imeni: [Glejte Prilogo I - izpolni država članica]
Long-term continuous infusion of Flolan should be administered through a central venous catheter.
Dolgotrajno stalno infundiranje zdravila Flolan mora potekati po centralnem venskem katetru.
The infusion rate is initiated at 2 nanograms/kg/min and increased by increments of 2 nanograms/kg/min every 15 min or longer until maximum haemodynamic benefit or dose-limiting pharmacological effects are elicited.
Infundiranje je treba začeti s hitrostjo 2 nanograma/kg/min in hitrost povečevati po 2 nanograma/kg/min vsakih 15 minut ali več, dokler niso doseženi ali največja hemodinamska korist ali največji, od odmerka omejeni farmakološki učinki.
The solvent contains no preservative; consequently a vial should be used once only and then discarded.
Vehikel ne vsebuje konzervansov, zato se sme vialo uporabiti le enkrat in jo je potem treba zavreči.
Renal Dialysis
Ledvična dializa
Dosage (nanograms/ kg/min)
Odmerek (nanogramov/ kg/min)
The change is thought to depend on both the basal heart rate and the concentration of Flolan administered.
Sprememba je verjetno odvisna od izhodiščne srčne frekvence in od uporabljene koncentracije zdravila Flolan.
The following schedule of infusion has been found effective in adults: Prior to dialysis: 4 nanograms/kg/min intravenously for 15 mins
Pri odraslih se je za učinkovitega izkazal naslednji razpored infundiranja: Pred dializo: 4 nanograme/kg/min intravensko 15 minut Med dializo: 4 nanograme/kg/min v arterijski vtok dializatorja
Conventional therapy varied among patients and included some or all of the following: anticoagulants in essentially all patients; oral vasodilators, diuretics, and digoxin in one half to two thirds of patients; and supplemental oxygen in about half the patients.
Obsegalo je nekatera od naslednjih zdravil: antikoagulantna zdravila (pri skoraj vseh bolnikih), peroralne vazodilatatorje, diuretike in digoksin (pri eni polovici do dveh tretjinah bolnikov) ter dodatni kisik (pri približno polovici bolnikov).
dosage (nanogram/kg/min) x bodyweight (kg)
odmerek (nanogramov/kg/min) x telesna masa (kg)
Except for 5 NYHA functional Class II patients, all patients were either functional Class III or Class IV.
funkcijskem razredu po NYHA, so bili vsi bolniki v III. ali IV. funkcijskem razredu.
a. Using concentrated solution, i.e. 10,000 nanograms/mL Flolan:
a. Uporaba koncentrirane raztopine, tj. 10.000 nanogramov zdravila Flolan/ml:
Clear (type 1) glass vials with synthetic butyl rubber stoppers and an external aluminium collar with a plastic flip-top cover.
Prozorne steklene viale (iz stekla tipa 1) z zamaški iz sintetične butilne gume z zunanjo aluminijsko obrobo in plastičnim snemnim pokrovčkom.
• blockage of the injection catheter
• zamašitev injekcijskega katetra.
4.5 Interaction with other medicinal products and other forms of interaction When Flolan is administered to patients receiving concomitant anticoagulants standard anticoagulant monitoring is advisable.
Če je zdravilo Flolan uporabljeno pri bolnikih, ki sočasno prejemajo antikoagulantna zdravila, so priporočljive standardne kontrole antikoagulantnega zdravljenja.
Where the infusion pump allows the use of a cold pouch, the solution may be used over a 24 hour period, provided the cold pouch is changed as necessary throughout the day.
Če infuzijska črpalka omogoča uporabo hladne vrečke, se lahko raztopino zdravila uporablja več kot 24 ur, pod pogojem, da se hladno vrečko tekom dneva menja, kot je potrebno.
Where a pack containing 1.5 mg Flolan is reconstituted with 50 mL solvent the resultant concentration is 30,000 nanograms/mL.
Če je pakiranje z 1,5 mg zdravila Flolan pripravljeno s 50 ml vehikla, je dobljena koncentracija 30.000 nanogramov/ml.
Sepsis, septicaemia (mostly related to delivery system for Flolan)1 Blood and Lymphatic System Disorders Common
Infekcijske in parazitske bolezni Pogosti sepsa, septikemija (najpogosteje povezana z aplikacijskim sistemom za zdravilo Flolan)1
When reconstituted and diluted as directed above, Flolan infusion solutions have a pH of approximately 10 and will retain 90% of their initial potency for approximately 12 hours at 25°C.
Po zgornjih navodilih pripravljena in razredčena raztopina za infundiranje zdravila Flolan ima pH približno 10 in pri temperaturi 25 °C ohrani 90 % svoje začetne učinkovitosti približno 12 ur.
The combined baseline 6-minute walk test median values for the conventional therapy group and epoprostenol plus conventional therapy group was 266 meters and 301 meters, respectively.
Kombinirana izhodiščna mediana vrednost 6-minutnega testa hoje je bila v skupini s kombinacijo konvencionalnega zdravljenja in epoprostenola 266 metrov in v skupini s samo konvencionalnim zdravljenjem 301 meter.
Dosage decreases should be made gradually in 2 nanograms/kg/min decrements every 15 min or longer until the dose-limiting effects resolve.
Odmerjanje je treba zmanjševati postopoma po 2 nanograma/kg/min vsakih 15 minut ali več, dokler učinki, ki omejujejo odmerek, ne minejo.
This medicinal product contains sodium, which should be taken into consideration by patients on a controlled sodium diet.
To je treba upoštevati pri bolnikih, ki so na dieti z nadzorovanim vnosom natrija.
MINIMUM PARTICULARS TO APPEAR ON IMMEDIATE PACKAGING LABEL for powder vial
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA STIČNI OVOJNINI NALEPKA za vialo s praškom
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON box for powder vials and solvent vials:
PODATKI NA ZUNANJI OVOJNINI ŠKATLA za viale s praškom in viale z vehiklom:
Conventional therapy varied among patients and included some or all of the following: anticoagulants in essentially all patients, supplemental oxygen and diuretics in two thirds of the patients, oral vasodilators in 40% of the patients, and digoxin in a third of the patients.
Obsegalo je nekatera od naslednjih zdravil: antikoagulantna zdravila (pri skoraj vseh bolnikih), dodatni kisik in diuretike (pri dveh tretjinah bolnikov), peroralne vazodilatatorje (pri 40 % bolnikov) in digoksin (pri tretjini bolnikov).
Flolan Injection comes in different strengths.
Zdravilo Flolan za injiciranje je na voljo v različnih jakostih.
• slow heart beat
• počasen srčni utrip,
• medicines used to dissolve blood clots
• zdravila za raztapljanje krvnih strdkov,
Gastrointestinal Disorders Very common Nausea, vomiting, diarrhoea Common
Bolezni prebavil Zelo pogosti navzea, bruhanje, driska
• feeling of tightness around the chest
• občutek tiščanja v prsih,
Withdraw approximately 10mL of the solvent into a sterile syringe, inject the contents of the syringe into the vial containing Flolan powder and shake gently until the powder has dissolved.
Izvlecite približno 10 ml vehikla v sterilno brizgo, vsebino brizge vbrizgajte v vialo, ki vsebuje prašek zdravila Flolan, in nežno pretresajte, dokler se prašek ne raztopi.
Powder for solution for infusion: Mannitol, glycine, sodium chloride, sodium hydroxide( for pH adjustment)
Prašek za raztopino za infundiranje: manitol, glicin, natrijev klorid, natrijev hidroksid (za prilagoditev pH) Vehikel za parenteralno uporabo: glicin, natrijev klorid, natrijev hidroksid (za prilagoditev pH), voda za injekcije
If you have any further questions, ask your doctor or pharmacist or nurse.
- Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom, s farmacevtom ali z medicinsko sestro.
Dilution:
Razredčenje:
• infection at the injection site
• okužba na mestu injiciranja.
The effects of epoprostenol on platelet aggregation is dose-related when between 2 and 16 nanograms/kg/min is administered intravenously, and significant inhibition of aggregation induced by adenosine diphosphate is observed at doses of 4 nanograms/kg/min and above.
Učinki intravensko uporabljenega epoprostenola na agregacijo trombocitov so v odmerkih od 2 do 16 nanogramov/kg/min odvisni od odmerka; pri odmerkih 4 nanograme/kg/min in več je opazno pomembno zavrtje agregacije, povzročene z adenozindifosfatom.
Patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with Flolan, which although transient, may be clinically significant in patients prone to digoxin toxicity.
Bolnikom, ki prejemajo digoksin, se lahko po uvedbi zdravljenja z zdravilom Flolan pojavi zvišanje koncentracije digoksina.
Other common intravenous fluids are unsatisfactory for the dilution of the concentrated solution as the required pH is not attained.
Druge pogoste intravenske tekočine za razredčenje koncentrirane raztopine niso primerne, ker ni dosežen potrebni pH. Raztopine zdravila Flolan so pri nizkem pH manj stabilne.
• 1.5 mg epoprostenol sodium.
• 1,5 mg natrijevega epoprostenolata.
Skin and Subcutaneous Tissue Disorders Common
Bolezni kože in podkožja Pogosti izpuščaj
Over 12 weeks, a statistical difference (p<0.001) in the change from baseline for the 6MWT was observed in the group receiving epoprostenol and conventional therapy as compared to the group receiving conventional therapy alone (median: 63.5 vs. -36.0 meters; mean: 42.9 vs. -40.7 meters).
V razponu 12 tednov so ugotovili statistično značilno razliko (p < 0,001) v spremembi 6-minutnega testa hoje v primerjavi z izhodiščem med skupino, ki je prejemala epoprostenol in konvencionalno zdravljenje, in skupino, ki je prejemala le konvencionalno zdravljenje (mediana: 63,5 v prim.
Flolan is injected into a vein.
Zdravilo Flolan se injicira v veno.
Infusion rates for a concentration of 5,000 nanograms/mL
Hitrosti infundiranja za koncentracijo 5.000 nanogramov/ml
Flolan is a potent inhibitor of platelet aggregation, therefore, an increased risk for haemorrhagic complications should be considered, particularly for patients with other risk factors for bleeding (see section 4.5).
Zato je treba upoštevati večje tveganje za zaplete zaradi krvavitve, zlasti pri bolnikih, ki imajo še druge dejavnike tveganja za krvavitev (glejte poglavje 4.5).
infusions may be used until central access is established.
Dokler ni nameščen centralni dostop, je mogoče uporabiti začasno periferno intravensko infuzijo.
Nineteen patients received 51 heparin dialyses and 19 received 44 epoprostenol dialyses in major controlled studies.
V velikih kontroliranih študijah je 19 bolnikov opravilo 51 dializ s heparinom, 19 pa 44 dializ z epoprostenolom.
10 mL concentrated solution + 40 mL sodium chloride 0.9% w/v solution.
10 ml koncentrirane raztopine + 40 ml 0,9 % (m/v) raztopine natrijevega klorida Dobljena koncentracija = 2.000 nanogramov zdravila Flolan/ml:
Store Flolan in a dry place.
Zdravilo Flolan shranjujte na suhem mestu.
EXP Read the package leaflet for the shelf-life of the reconstituted/diluted product
EXP Glede roka uporabnosti pripravljenega/razredčenega zdravila preberite navodilo za uporabo
Epoprostenol 1.5mg Powder for Solution for Infusion:
Epoprostenol 1,5 mg prašek za raztopino za infundiranje:
When 0.5 mg Flolan powder is reconstituted with 50 mL of the solvent, the final injection has a pH of approximately 10.5 and a sodium ion content of approximately 56 mg.
Če 0,5 mg zdravila Flolan pripravite s 50 ml vehikla, ima končna raztopina za injiciranje pH približno 10,5 in vsebuje približno 56 mg natrijevih ionov.
Initially, a pack containing solvent must be used.
Uvodoma je treba uporabiti pakiranje, ki vsebuje vehikel.
Abrupt withdrawal of Flolan or sudden large reductions in infusion rates should be avoided due to the risk of potential fatal rebound effect (see section 4.4).
Zaradi možnosti smrtnega preobratnega učinka ("rebound") se zdravila Flolan ne sme nenadoma prenehati uporabljati; prav tako se ne sme nenadoma močno zmanjšati hitrosti infundiranja (glejte poglavje 4.4).
It is possible to refrigerate Flolan reconstituted solutions, before they are used at room temperature, ranging between 2°C and 8°C and without exceeding 40 hour storage.
Pripravljeno raztopino zdravila Flolan je mogoče pred uporabo pri sobni temperaturi shranjevati v hladilniku pri temperaturi od 2 do 8 °C; takšno shranjevanje ne sme trajati več kot 40 ur.
While you are being treated with Flolan it is important that you check the injection area.
Pomembno je, da med zdravljenjem z zdravilom Flolan preverjate mesto injiciranja.
Because of the high pH of the final infusion solutions, care should be taken to avoid extravasation during their administration and consequent risk of tissue damage.
4.4 Posebna opozorila in previdnostni ukrepi pH končne raztopine za infundiranje je visok, zato je treba paziti, da med dajanjem ne pride do ekstravazacije in posledične okvare tkiva.
Withdraw approximately 10 mL of the solvent into a sterile syringe, inject it into the vial containing 0.5 mg freeze-dried Flolan powder and shake gently until the powder has dissolved.
Izvlecite približno 10 ml vehikla v sterilno brizgo, vbrizgajte ga v vialo, ki vsebuje 0,5 mg liofiliziranega praška zdravila Flolan, in nežno pretresajte, dokler se prašek ne raztopi.
• You have fevers or chills.
• Imate zvišano telesno temperaturo ali mrzlico.
The pack suitable for use in renal dialysis contains 0.5 mg freeze-dried Flolan plus 50 mL solvent.
Pakiranje, primerno za uporabo pri ledvični dializi, vsebuje 0,5 mikrograma liofiliziranega zdravila Flolan in 50 ml vehikla.
Kidney dialysis You will be given an infusion of Flolan for the duration of your dialysis.
Ledvična dializa Infuzijo zdravila Flolan boste dobili, medtem ko bo potekala dializa.
The active substance is epoprostenol sodium.
Zdravilna učinkovina je natrijev epoprostenolat.
Very common side effects These may affect more than 1 in 10 people:
Zelo pogosti neželeni učinki Ti se lahko pojavijo pri več kot 1 od 10 oseb:
Flolan contains Sodium.
Zdravilo Flolan vsebuje natrij.
This is where the pressure is high in the blood vessels in the lungs.
Pri tej bolezni je tlak v pljučnem ožilju previsok.
Each vial contains epoprostenol sodium equivalent to 0.5 mg epoprostenol.
Ena viala vsebuje natrijev epoprostenolat, kolikor ga ustreza 0,5 mg epoprostenola.
Statistically significant improvement was observed in exercise capacity (p=0.001), as measured by the 6MWT in patients receiving continuous intravenous epoprostenol plus conventional therapy (N=52) for 8 or 12 weeks compared to those receiving conventional therapy alone (N=54) (combined week 8 and 12 change from baseline - median: 49 vs. -4 meters; mean: 55 vs. -4 meters).
Pri bolnikih, ki so stalno prejemali intravenski epoprostenol obenem s konvencionalnim zdravljenjem (n = 52) 8 ali 12 tednov, so v primerjavi z bolniki, ki so prejemali le konvencionalno zdravljenje (n = 54) zabeležili statistično značilno izboljšanje obremenitvene zmogljivosti (p = 0,001), merjene s 6-minutnim testom hoje (kombinirana sprememba od izhodišča za 8. in 12. teden - mediana: 49 v prim.
Sterile technique must be adhered to in preparing the drug and in the care of the catheter.
Pri pripravi zdravila in oskrbi katetra je treba upoštevati sterilen postopek.
Looking after the injection line
Skrb za injekcijski kateter
Nervous System Disorders Very common Headache Cardiac Disorders Common
Bolezni živčevja Zelo pogosti glavobol
The median baseline value for the conventional therapy group and epoprostenol plus conventional therapy group was 240 meters and 270 meters, respectively.
Izhodiščna mediana vrednost 6-minutnega testa hoje je bila v skupini s konvencionalnim zdravljenjem 240 metrov in v skupini s kombinacijo konvencionalnega zdravljenja in epoprostenola 270 metrov.
• One vial containing sterile, freeze-dried Flolan equivalent to 1.5 mg Flolan, supplied with one or two 50 mL vials of solvent and a filter unit.
• Ena viala s sterilnim liofiliziranim zdravilom Flolan, kolikor ustreza 1,5 mg zdravila Flolan, z eno ali dvema 50-ml vialama vehikla in filtrirno enoto.
Each vial contains epoprostenol sodium equivalent to 1.5 mg epoprostenol.
Ena viala vsebuje natrijev epoprostenolat, kolikor ga ustreza 1,5 mg epoprostenola.
If you get any side effects , talk to your doctor or pharmacist or nurse.
- Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom, s farmacevtom ali z medicinsko sestro.
Dispense the concentrated solution directly into the chosen infusion solution using firm but not excessive pressure; the typical time taken for filtration of 50 mL of concentrated solution is 70 seconds.
Koncentrirano raztopino dajte neposredno v izbrano raztopino za infundiranje z odločnim, a ne premočnim pritiskom; običajni čas za filtriranje 50 ml koncentrirane raztopine je 70 sekund.
Draw up the resulting Flolan solution into the syringe, re-inject it into the remaining volume of the solvent and mix thoroughly.
Nastalo raztopino zdravila Flolan potegnite v brizgo in jo ponovno injicirajte v preostalo količino vehikla ter temeljito premešajte.
Dispense the concentrated solution directly into the solvent using firm but not excessive pressure; the typical time taken for filtration of 50 mL of concentrated solution is 70 seconds.
Koncentrirano raztopino dajte neposredno v vehikel z odločnim, a ne premočnim pritiskom; običajni čas za filtriranje 50 ml koncentrirane raztopine je 70 sekund.
• pain at the injection site
• bolečina na mestu injiciranja.
What Flolan contains
Kaj vsebuje zdravilo Flolan
Keep dry.
Shranjujte na suhem mestu.
Chronic continuous infusions of epoprostenol in patients with idiopathic or heritable PAH were studied in 2 prospective, open, randomised trials of 8 and 12 weeks' duration (N=25 and N=81, respectively) comparing epoprostenol plus conventional therapy to conventional therapy alone.
Kronično stalno infundiranje epoprostenola pri bolnikih z idiopatsko ali dedno PAH so raziskali v 2 prospektivnih, odprtih randomiziranih preskušanjih, ki sta trajali 8 tednov (n = 25) in 12 tednov (n = 81).
Breast-feeding should be discontinued during treatment with Flolan.
Med zdravljenjem z zdravilom Flolan je treba dojenje prekiniti.
• 0.5 mg epoprostenol sodium
• 0,5 mg natrijevega epoprostenolata ali
Contact the hospital immediately for advice if the area becomes sore, painful or swollen or you notice any blistering or shedding.
Če se mesto injiciranja vname, boli ali oteče, ali če opazite mehurje ali lupljenje, se za nasvet nemudoma obrnite na bolnišnico.
No statistical difference in survival over 12 weeks was observed in PAH/SSD patients treated with epoprostenol as compared to those receiving conventional therapy alone.
Primerjava bolnikov s PAH/SSD, zdravljenih z epoprostenolom in zdravljenih s konvencionalnim zdravljenjem samim, v 12 tednih ni pokazala statistične razlike glede preživetja.
Example For Dosing Using a Concentration of 5,000 nanograms/mL Dosage (nanograms/ kg/ min)
Primer za odmerjanje z uporabo koncentracije 5.000 nanogramov/ml Odmerek (nanogramo v/kg/min)
Powder for solution for infusion: Clear (type 1) glass vials with synthetic butyl rubber stoppers and an aluminium collar with a snap-off top.
Prozorne steklene viale (iz stekla tipa 1) z zamaški iz sintetične butilne gume z aluminijsko obrobo in snemnim pokrovčkom.
In general, dose selection for an elderly patient should be made carefully, reflecting the greater frequency of decreased hepatic, renal (in the case of pulmonary arterial hypertension) or cardiac function and of concomitant disease or other medicine therapy.
Specifičnih informacij o uporabi zdravila Flolan pri ledvični dializi ali pljučni arterijski hipertenziji pri bolnikih, starejših od 65 let, ni. Na splošno je treba odmerek za starejše bolnike določiti skrbno, upoštevaje večjo pogostnost zmanjšanega delovanja jeter, ledvic (v primeru pljučne arterijske hipertenzije) ali srca ter sočasne bolezni ali uporabo drugih zdravil.
There are four packs available for use in the treatment of pulmonary arterial hypertension, as follows:
Za zdravljenje pljučne arterijske hipertenzije so na voljo naslednja štiri pakiranja:
• heart beating faster
• hitrejši srčni utrip,
Flolan may be used either as concentrated solution or in a diluted form for the treatment of pulmonary arterial hypertension.
Zdravilo Flolan se za zdravljenje pljučne arterijske hipertenzije lahko uporablja kot koncentrirana raztopina ali v razredčeni obliki.
This solution is now referred to as the concentrated solution and contains 10,000 nanograms/mL Flolan.
Nastalo raztopino imenujemo koncentrirana raztopina in vsebuje 10.000 nanogramov zdravila Flolan/ml.
One ml of reconstituted concentrate solution contains epoprostenol (as epoprostenol sodium) 10 000 nanogram.
En mililiter pripravljenega koncentrata raztopine vsebuje 10.000 nanogramov epoprostenola (kot natrijevega epoprostenolata).
• feeling agitated
• vznemirjenost,
None of the dialyses using heparin and 5% (n=32) of dialyses using epoprostenol had minor clotting.
Manj pomembno strjevanje se ni pojavilo pri nobeni dializi s heparinom in pri 5 % (n = 32) dializ z epoprostenolom.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Each vial contains 0.5mg epoprostenol (as epoprostenol sodium) Each vial contains 1.5mg epoprostenol (as epoprostenol sodium)
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT Ena viala vsebuje 0,5 mg epoprostenola (kot natrijevega epoprostenolata)
In major controlled studies, when all dialyses were combined for each treatment (heparin or epoprostenol), more heparin patients bled during the day prior to dialysis (N=13/17 vs. 8/23), dialysis day (N=25/28 vs. 16/35) and the day following dialysis (N=16/24 vs. 5/24) than epoprostenol patients during the same time periods.
V velikih kontroliranih študijah je (vse dialize skupaj za vsako zdravljenje - heparin ali epoprostenol) imelo v enakih časovnih obdobjih več prejemnikov heparina kot prejemnikov epoprostenola krvavitev dan pred dializo (n = 13/17 v prim.
Only the 0.5 mg pack is suitable for use in renal dialysis.
Ledvična dializa Za uporabo pri ledvični dializi je primerno samo pakiranje 0,5 mg.
Sodium chloride 0.9% w/v solution must not be used when Flolan is to be used for the treatment of pulmonary arterial hypertension.
Če je zdravilo Flolan uporabljeno za zdravljenje pljučne arterijske hipertenzije, se ne sme uporabljati 0,9 % (m/v) raztopine natrijevega klorida.
• redness of your face (flushing)
• pordelost obraza (zardevanje).
Except for 2 New York Heart Association (NYHA) functional Class II patients, all patients were either functional Class III or Class IV. As results were similar in the 2 studies, the pooled results are described.
funkcijskem razredu po NYHA (New York Heart Association), so bili vsi bolniki v III. ali IV. funkcijskem razredu.
• One 1.5 mg powder vial.
• ena viala z 1,5 mg praška.
• One vial containing sterile, freeze-dried Flolan equivalent to 0.5 mg Flolan supplied alone.
• Ena viala s sterilnim liofiliziranim zdravilom Flolan, kolikor ustreza 0,5 mg zdravila Flolan, samim.
• diarrhoea
• oteklost,
Seek urgent medical attention if you think you have used or been given too much Flolan.
Če menite, da ste uporabili ali da ste dobili preveč zdravila Flolan, nemudoma poiščite zdravniško pomoč.
You should stop breastfeeding your child during treatment with Flolan.
Med zdravljenjem z zdravilom Flolan morate nehati dojiti.
2 Tachycardia has been reported as a response to Flolan at doses of 5 nanograms/kg/min and below.
2 Kot odziv na zdravilo Flolan v odmerkih 5 nanogramov/kg/min in manj je bila opisana tahikardija.
Flolan 0.5 mg powder for solution for infusion Flolan 1.5 mg powder for solution for infusion Intravenous use
Flolan 0,5 mg prašek za raztopino za infundiranje Flolan 1,5 mg prašek za raztopino za infundiranje intravenska uporaba epoprostenol
A statistically significant increase in CI, and statistically significant decreases in PAPm, RAPm, PVR, and SAPm after 12 weeks of treatment were observed in patients who received epoprostenol chronically compared to those who did not.
Pri bolnikih, ki so kronično prejemali epoprostenol, so v primerjavi z bolniki, ki ga niso prejemali, po 12 tednih zdravljenja ugotovili statistično značilno povečanje CI ter statistično značilno zmanjšanje PAPm, RAPm, PVR in SAPm .